anti cd27l antibody drug conjugate amg 172

Drug Overview

The medication known as anti cd27l antibody drug conjugate amg 172 (also identified as AMG 172) is an investigational, first-in-class immunotherapy designed to treat advanced kidney cancer. It belongs to the Antibody-Drug Conjugate (ADC) family, actings as a molecular “guided missile” that combines a highly specific antibody with a potent cell-killing agent.

Developed by Amgen, AMG 172 was specifically engineered to target CD27L (also known as CD70), a protein that is often overexpressed in certain aggressive tumors but has very limited presence on healthy tissues. By targeting this “biological marker,” the drug aims to deliver a lethal dose of chemotherapy directly into the heart of the cancer cell while attempting to reduce the “collateral damage” usually seen with traditional chemotherapy.

• Generic Name: AMG 172.
• Drug Class: Antibody-Drug Conjugate (ADC) / Microtubule Inhibitor.
• Target: CD27L (CD70 / Tumor Necrosis Factor Ligand Superfamily Member 7).
• Payload: Maytansinoid DM1 (Mertansine).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational/Discontinued. As of 2026, AMG 172 is not FDA-approved. Clinical development was largely discontinued following Phase I trials. While the drug reached its biological target, the “therapeutic window”—the balance between a safe dose and an effective one—was found to be too narrow, and the clinical response in patients was limited.

What Is It and How Does It Work? (Mechanism of Action)

The CD27L (CD70) Target

CD27L is a protein found on the surface of several types of solid and liquid tumors, particularly Clear Cell Renal Cell Carcinoma (ccRCC). In healthy adults, it is only found temporarily on certain activated immune cells. This makes it an ideal “ZIP code” for a drug to find and attach to kidney cancer.

Molecular Level Mechanisms

1. Selective Binding: After being infused into the blood, AMG 172 circulates until it finds a cell displaying the CD27L protein. The humanized IgG1 antibody portion locks onto the receptor.
2. Internalization: The cancer cell “swallows” the drug-receptor complex through a process called endocytosis, bringing the drug inside.
3. Payload Release: Inside the cell’s lysosomes, the drug is broken down, releasing the toxic payload, DM1, into the cell’s interior (cytoplasm).
4. Microtubule Disruption: DM1 is a powerful microtubule inhibitor. It binds to tubulin and prevents the cell from building the internal “skeleton” it needs to divide.
5. Cell Cycle Arrest: This “handcuffs” the cell during the G2/M phase, making it impossible for the cell to complete division.
6. Apoptosis: The cell eventually recognizes it cannot divide and commits “programmed suicide” (apoptosis).

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for AMG 172.

During its clinical life, it was investigated for:

• Relapsed or Refractory Clear Cell Renal Cell Carcinoma (ccRCC): Specifically for patients who had failed at least two prior standard therapies (like sunitinib or pazopanib).

Dosage and Administration Protocols

Because the drug was discontinued during Phase I, there is no established “Standard of Care” dose. The following information is based on the protocols used during its dose-exploration research.

Clinical Efficacy and Research Results

The clinical journey of AMG 172 provided vital data on the feasibility of targeting CD70.

• Activity Results: In the pivotal Phase I trial of 37 patients, the objective response was considered limited. Only 2 patients (5.4%) achieved a “Partial Response,” while 6 patients (16.2%) maintained “Stable Disease.”
• Target Delivery: Pharmacokinetic studies showed that the drug successfully reached the tumors; however, the level of cell-killing was not strong enough to overcome the aggressive nature of refractory kidney cancer.
• Evolution of the Class: The lessons learned from AMG 172 have led to newer CD70-targeting CAR-T cells and more potent ADCs (like SGN-CD70A) currently in 2026 clinical trials.

Safety Profile and Side Effects

The primary challenge for AMG 172 was managing the balance between tumor killing and “off-target” effects on healthy blood and liver cells.

Common Side Effects (>30%):

• Thrombocytopenia: A significant drop in blood platelet counts (reported in 59% of patients).
• Nausea and Vomiting: Gastrointestinal upset (reported in ~50%).
• Decreased Appetite.
• Fatigue: A general sense of tiredness (35%).

Serious Adverse Events (Dose-Limiting):

• Severe Thrombocytopenia: This was the most frequent reason for stopping treatment or lowering the dose.
• Hepatocellular Injury: Spikes in liver enzymes (ALT/AST) or actual liver damage occurred in several patients at the higher dose levels (1.6 mg/kg and 2.4 mg/kg).

Research Areas

In the field of Stem Cell and Regenerative Medicine, the CD27L/CD70 pathway is a major focus for understanding “Cancer Stem Cells.” Researchers are investigating whether CD70 is a marker for the most resilient kidney cancer stem cells that survive surgery. By understanding why AMG 172 had limited success, scientists are now designing “Bystander Effect” ADCs. These newer drugs release toxins that can leak out of a dying cancer cell to kill nearby resistant cells in the “tumor microenvironment,” potentially leading to true regeneration of healthy kidney tissue.

Patient Management and Practical Recommendations

Pre-treatment Tests (Historically Required):

• Baseline Platelet Count: Critical, as the drug significantly lowers platelets.
• Liver Function Tests (LFTs): Essential to monitor for liver injury.
• Renal Function: Monitoring the health of the remaining kidney tissue.

Precautions:

• Bleeding Risk: Due to low platelets, patients had to be careful with activities that could cause bruising or bleeding.
• Dose Holds: Doctors frequently had to skip or delay doses if liver enzymes or platelets had not recovered from the previous cycle.

“Do’s and Don’ts” List:

• DO report any unusual bruising, nosebleeds, or tiny red spots on the skin (petechiae) immediately.
• DO keep track of your appetite; nutritional support was often needed during the Phase I trials.
• DON’T ignore a yellowing of the eyes (jaundice) or dark urine, as these are signs of liver stress.
• DON’T start any new medications that affect blood clotting (like aspirin) without consulting your oncologist.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. AMG 172 is an investigational agent that has been largely discontinued from active clinical development. It is not approved by the US Food and Drug Administration (FDA) for any indication. Always consult with a qualified oncologist regarding currently available and approved treatments for renal cell carcinoma.